New Pancreatic Cancer Drugs Could Arrive This Year

A genetic mutation that scientists have chased for decades may finally have met its match, bringing new hope to tens of thousands of people facing pancreatic cancer each year.

More than 60 drugs targeting KRAS mutations are now in development, with some potentially reaching patients as early as 2026. These mutations appear in over 90% of pancreatic cancers, making them one of the most important targets researchers have identified.

"The most exciting thing that's going on right now is that some of the most common genetic mutations we know of in pancreatic cancer are finally having drugs that seem to work against them," says Dr. Robert McWilliams, Deputy Director of OSF HealthCare Cancer Institute in Peoria, Illinois. The new class of medications, called KRAS inhibitors, are currently in Phase 3 clinical trials.

KRAS is a gene that normally acts like a growth switch in cells, turning on when the body needs new cells and off when it doesn't. But when KRAS mutates, that switch gets stuck in the "on" position, causing cells to grow nonstop and form tumors.

The FDA has already granted special priority status to one promising drug called daraxonrasib, which is being tested specifically for pancreatic cancer patients. Revolution Medicines, the company developing the treatment, is running global trials to evaluate its effectiveness in people with advanced disease.

This progress marks a dramatic shift for a cancer that has historically been extremely difficult to treat. According to the National Cancer Institute, only 13.3% of people survive five years after a pancreatic cancer diagnosis. Nearly 68,000 Americans were diagnosed in 2025, and about 52,000 died from the disease.

Part of what makes pancreatic cancer so deadly is its silence. The disease often causes no specific symptoms until it has already spread, which is why Dr. McWilliams urges people to pay attention to warning signs like unexplained weight loss or painless jaundice.

Why This Inspires

For decades, families touched by pancreatic cancer have watched other cancer treatments advance while progress against this disease moved painfully slowly. These new KRAS inhibitors represent something different: a targeted approach based on understanding the genetic engine driving most pancreatic tumors. Researchers are also developing therapeutic cancer vaccines that help the immune system fight back, with early results showing real promise. The convergence of these approaches suggests we may be entering a new era where pancreatic cancer becomes more manageable, giving patients more time with the people they love.

Scientists are also working on treatments that can target multiple KRAS mutations at once, which could help even more patients. Nearly half of all pancreatic cancer cases involve a specific mutation called KRAS-G12D, making it a priority target.

While researchers race toward better treatments, Dr. McWilliams emphasizes that lifestyle choices matter too. Not smoking, avoiding excessive alcohol, maintaining a healthy weight, and staying physically active can reduce cancer risk and improve outcomes for those already diagnosed.

The path from clinical trials to widespread availability takes time, but for the first time in years, there's genuine reason for optimism in the fight against pancreatic cancer.